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Research
AbstrACt
Objective To assess the fidelity of general practitioners’ 
(GPs) adherence to a long-term pragmatic trial protocol.
Design  Retrospective analyses of electronic primary 
care records of participants in the pragmatic cluster-
randomised ADDITION (Anglo-Danish-Dutch Study of 
Intensive Treatment In People with Screen Detected 
Diabetes in Primary Care)-Cambridge trial, comparing 
intensive multifactorial treatment (IT) versus routine care 
(RC). Data were collected from the date of diagnosis until 
December 2010.
setting  Primary care surgeries in the East of England. 
study sample/participants  A subsample (n=189, 
RC arm: n=99, IT arm: n=90) of patients from the 
ADDITION-Cambridge cohort (867 patients), consisting of 
patients 40–69 years old with screen-detected diabetes 
mellitus. 
Interventions  In the RC arm treatment was delivered 
according to concurrent treatment guidelines. Surgeries 
in the IT arm received funding for additional contacts 
between GPs/nurses and patients, and GPs were advised 
to follow more intensive treatment algorithms for the 
management of glucose, lipids and blood pressure and 
aspirin therapy than in the RC arm. 
Outcome measures  The number of annual contacts 
between patients and GPs/nurses, the proportion of 
patients receiving prescriptions for cardiometabolic 
medication in years 1–5 after diabetes diagnosis and the 
adherence to prescription algorithms. 
results The difference in the number of annual GP 
contacts (β=0.65) and nurse contacts (β=−0.15) between 
the study arms was small and insignificant. Patients in 
the IT arm were more likely to receive glucose-lowering 
(OR=3.27), ACE-inhibiting (OR=2.03) and lipid-lowering 
drugs (OR=2.42, all p values <0.01) than patients in 
the RC arm. The prescription adherence varied between 
medication classes, but improved in both trial arms over 
the 5-year follow-up.
Conclusions The adherence of GPs to different aspects 
of the trial protocol was mixed. Background changes in 
healthcare policy need to be considered as they have the 
potential to dilute differences in treatment intensity and 
hence incremental effects.
trial registration number ISRCTN86769081.
bACkgrOunD 
Type 2 diabetes is an increasing public health 
problem associated with premature mortality 
and costly microvascular and macrovascular 
complications in terms of both reduced 
quality of life and financial burden, causing 
substantial economic pressure on healthcare 
systems and societies.1–4
Previous research has shown that inten-
sive treatment of cardiovascular risk factors 
is an effective and cost-effective intervention 
for patients with long-standing diabetes or 
routinely diagnosed diabetes.5–8 In contrast, 
little was known about the effectiveness 
and cost-effectiveness of intensive primary 
care-based treatment in patients in the early 
stages of the disease, such as screen-detected 
populations. The pragmatic cluster-ran-
domised ADDITION (Anglo-Danish-Dutch 
Study of Intensive Treatment In People with 
Screen Detected Diabetes in Primary Care) 
trial (ISRCTN86769081) was one of the first 
strengths and limitations of this study
 ► Pragmatic trials aim to produce externally valid re-
sults for decision makers. If and to what extent prag-
matic trial interventions are delivered to patients 
often remains unknown.
 ► This study describes the adherence of general 
practitioners to the ADDITION trial protocol  (Anglo-
Danish-Dutch Study of Intensive Treatment In People 
with Screen Detected Diabetes in Primary Care), and 
hence provides a unique insight about what we can 
expect in future long-term pragmatic studies in the 
primary care context, particularly in the context of 
policy and guideline changes.
 ► Analyses are based on a subsample of participants 
of the ADDITION-Cambridge trial conducted in the 
East of England. Therefore, the generalisability of 
results might be limited.
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studies addressing this important question.9–11 Results 
showed that, compared with routine care, early intensive 
treatment modestly improved levels of cardiovascular risk 
factors, but did not significantly reduce the incidence of 
cardiovascular events, microvascular complications and 
cardiovascular/overall mortality over the 5-year study 
period.12–14
Pragmatic trials aiming to generate externally valid 
evidence in a real-world setting, such as ADDITION, always 
present uncertainties concerning the implementation of 
the planned interventions in daily practice. Unlike highly 
controlled efficacy trials in which compliance to an (simple, 
one-dimensional) intervention can (and must) be assured, 
the purpose of pragmatic trials is to assess the effectiveness 
of an (complex, multifactorial) intervention in routine 
settings. In the ADDITION-Cambridge trial, intensive treat-
ment (IT) was compared with routine care (RC) for patients 
with screen-detected diabetes. IT in ADDITION was a 
multifactorial intervention including treatment targets and 
treatment algorithms that were more intensive than those 
in contemporary UK national treatment guidelines, as well 
as educational material for patients.10 15–17 However, the 
degree to which protocol components were implemented 
into practice, and hence the degree to which more inten-
sified treatment was actually provided to patients in the 
intervention arm, has remained unknown. Furthermore, 
potential changes in national treatment guidelines towards 
more intensive care, and the introduction of the pay for 
performance system in England within the national Quality 
and Outcomes Framework (QOF),18 19 are likely to have 
improved routine care and may have diluted the difference 
in treatment intensity between the study arms over time.20
Beyond improving understanding of the results of the 
ADDITION-Cambridge study, knowledge about whether 
and how the intervention was actually delivered in practice 
can inform future pragmatic trials in relation to barriers to 
protocol adherence, and the difference in treatment inten-
sity that can be expected in a primary care-based pragmatic 
trial in the context of background policy changes.
The objective of this study was therefore to describe 
the adherence of general practitioners (GPs) to the trial 
protocol and to compare the intensity of care delivered 
to patients with screen-detected diabetes between the trial 
arms.
MethODs
study design
The ADDITION-Cambridge study protocol has been 
published elsewhere.10 In brief, ADDITION-Cambridge 
is part of the ADDITION-Europe trial, which consisted 
of two phases: a screening programme and a pragmatic, 
cluster-randomised trial comparing the effect of early IT 
versus RC on 5-year cardiovascular risk in patients with 
screen-detected type two diabetes mellitus.9 The primary 
endpoint was a composite of cardiovascular morbidity 
Figure 1 Study design. GP, general practitioner.
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and mortality (cardiovascular death, non-fatal myocardial 
infarction, non-fatal stroke, non-traumatic amputations 
and revascularisations).
study population
For ADDITION-Cambridge, 33 539 eligible individuals 
were invited to stepwise screening. Individuals eligible 
for screening were people registered at one of the partic-
ipating general surgeries around Cambridge, aged 40–69 
years, not known to have diabetes and with a diabetes 
risk score of >0.17 (corresponding to the top 25% of the 
population distribution). The risk score included age, 
sex, body mass index, steroid and antihypertensive medi-
cation, as well as smoking and family history.21 Exclusion 
criteria were assessed by the potential participant’s GP. 
Patients with severe illness with a life expectancy of less 
than 12 months, those with psychological or psychiatric 
disorders that might invalidate informed consent, and 
those who were housebound, pregnant or breast feeding 
were excluded from the study. Eight hundred and 
sixty-seven eligible patients (from n=49 surgeries) with 
screen-detected diabetes participated in the pragmatic 
primary care-based intervention trial. Written informed 
consent was obtained from all participants. This trial is 
registered as ISRCTN86769081.
Due to the high expenses of assessing and extracting 
data from electronic primary care records, it was decided 
in the planning phase of the ADDITION-Cambridge 
study that only the records of a subset of the study will be 
assessed. It was decided that the records of participants 
with a primary endpoint within the 5 years of follow-up 
plus the records of two random participants without 
a primary endpoint from the same GP surgery will be 
accessed. Consequently, the records of 63 participants 
with a primary endpoint (30 from the IT arm and 33 from 
the RC arm) and of 126 participants without a primary 
endpoint (60 from the IT arm and 66 from the RC arm) 
were collected. This selection procedure led in total to 
a subsample of 189 participants (IT: n=90 patients, RC: 
n=99 patients) from 34 surgeries (IT: 18 GP surgeries, 
RC: 16 GP surgeries). The study design is illustrated in 
detail in figure 1.
Table 1 Criteria for the initiation of glucose-lowering, blood pressure-lowering, lipid-lowering and platelet-inhibiting (aspirin) 
medication according to the trial protocol (IT arm) and national guidelines (RC arm)*
Glucose-
lowering therapy
Blood pressure-lowering 
therapy Lipid-lowering therapy
CVD risk-lowering 
aspirin therapy
Routine care (RC) – if HbA1c ≥7%† – if BP ≥160/100
– if 140/80 mm Hg ≤BP < 
160/100 mm Hg and either 
prevalent CVD or 10-year CHD 
risk ≥15%
(ACE inhibitors, ARBs, beta-
blockers or diuretics as first 
choice)
– if total 
cholesterol ≥5 mmol/L or 
triglycerides ≥2.3 mmol/L
– if prevalent CVD or 10-
year CHD risk ≥15%
– if prevalent CVD or 10-
year CHD risk ≥15%
Intensive treatment 
(IT)
– if HbA1c ≥6.5% – if ≥120/80 mm Hg or prevalent 
CVD
(ACE inhibitors/ARBs as first 
choice)
– if total 
cholesterol ≥3.5 mmol/L
– independent of risk 
profile
This figure does not claim to comprehensively describe the national treatment algorithms from the year 2002 or the detailed ADDITION trial 
protocol. It only highlights the differences in criteria for the initiation of drug therapy between IT and RC and does not account for possible 
contraindications.
*Criteria are based on the national treatment guidelines from 200215–17 and the ADDITION trial protocol.10
†A range of 6.5%–7.5% was mentioned. Consequently, the arithmetic mean of the borders (7%) was used as threshold.
ADDITION, Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care; ARB, angiotensin 
receptor blockers; BP, blood pressure; CHD, coronary heart disease; CVD, cardio-vascular disease; HbA1c, glycated haemoglobin.
Table 2 Baseline characteristics of the used subsample of 
ADDITION-Cambridge
Intensive 
treatment Routine care
N 82 91
Female sex, 
 n (%) 30 (36.6) 30 (30.3)
Caucasian ethnicity, n 
(%) 77 (93.9) 96 (97)
Age, mean (SD) 61.87 (7.28) 62.01 (6.81)
BMI (kg/m2), mean (SD) 33.6 (5.6) 33.8 (5.9)
Total cholesterol 
(mmol/L), mean (SD) 5.47 (1.12) 5.46 (1.22)
HDL cholesterol 
(mmol/L), mean (SD) 1.16 (0.32) 1.2 (0.31)
Systolic blood pressure 
(mm Hg), mean (SD) 143 (20.8) 143.8 (22.2)
HbA1c(%), mean (SD) 7.84 (2.09) 7.27 (1.59)
ADDITION, Anglo-Danish-Dutch Study of Intensive Treatment In 
People with Screen Detected Diabetes in Primary Care; BMI, body 
mass index; HbA1c, glycated haemoglobin; HDL, high-density 
lipoprotein; N, number of individuals included in the analysis 
sample.
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It and rC
Patients were treated according to the treatment allo-
cation of their surgery. In the RC arm patients received 
diabetes care through the National Health Service 
according to current UK guidelines and recommenda-
tions.15–17 In the IT arm additional features were added 
to current RC:
a. Surgeries received funding for three additional 10 min 
GP consultations and three additional nurse consulta-
tions per year in the first 3 years after diagnosis.
b. Treatment algorithms were introduced along with un-
derlying evidence demonstrating positive effects on 
cardio-vascular disease (CVD) risk factors among pa-
tients with type 2 diabetes. In the IT arm therapy with 
glucose-lowering medication was indicated if glycated 
haemoglobin (HbA1c) ≥6.5%; ACE inhibitors/angio-
tensin receptor blockers (ARBs) if blood pressure (BP) 
≥120/80 mm Hg; statins if cholesterol ≥3.5 mmol/L; 
and aspirin for all patients independent of their risk 
factor levels (assuming that patients had no contra-
indications). The thresholds for treatment initiation 
for glucose-lowering, BP-lowering and lipid-lowering 
medication and for aspirin therapy in both the IT arm 
(based on the trial protocol10) and the RC arm (based 
on national guidelines15–17) are summarised in table 1.
c. 3. Practice teams received theory-based education-
al materials to hand over to the patients, aiming to 
provide a shared framework for the management of 
their disease. Furthermore, GPs were advised to refer 
patients to a dietitian, and patients were encouraged 
through their GPs and nurses to increase their phys-
ical activity, to avoid excessive alcohol intake, to lose 
weight, to stop smoking, to adhere to medication and 
to self-monitor blood glucose if given a glucometer by 
their GP.
Intensive treatment was promoted to participating 
surgeries by practice-based educational meetings with 
GPs and nurses. This included initial practice-based 
academic detailing conducted by a diabetologist and 
an academic GP to introduce treatment algorithms, 
and two interactive practice-based feedback sessions 
(approximately 6 and 14 months after the initial educa-
tion session) to support and monitor treatment delivery.
Measures of treatment intensity
Information on the intensity of delivered care was extracted 
from the electronic primary care records of participating 
Figure 2 Contact with primary care professionals. 
 o
n
 12 N
ovem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-015295 on 14 June 2018. Downloaded from 
5Laxy M, et al. BMJ Open 2018;8:e015295. doi:10.1136/bmjopen-2016-015295
Open access
patients from the date of the diabetes diagnosis until 
December 2010 by a researcher blind to the GP surgery 
study group allocation. These files recorded the date and 
type of delivered services, including consultations with 
primary care health professionals, prescribed medications 
and laboratory measurements/tests. For the analysed trial 
population more than 80 000 observations were available in 
the first 5 years after diagnosis. Clear text functions were 
used and algorithms were derived to classify the obtained 
information. Ambiguous observations were screened and 
coded by hand. Anatomic Therapeutic Chemical codes 
were assigned to drugs to categorise medication classes. 
The intensity of care indicators was defined as follows:
Contact with healthcare professionals
The annual number of contacts between patients and 
GPs (including GP partners, GP principals, GP associates 
and out-of-hours doctors) and nurses (including practice 
nurses, nurse practitioners and nurse specialists). This 
included all contacts as we were unable to distinguish 
those related to diabetes alone.
Medication
Continuous treatment (≥4 prescriptions annually) with 
glucose-lowering drugs (metformin, sulfonylurea, thiazo-
lidinedione, insulin, other glucose-lowering drugs), 
ACE-inhibiting drugs (ACE inhibitors or ARBs), lipid-low-
ering drugs (statins, other cholesterol-lowering drugs) or 
aspirin.
Monitoring of risk factor levels
Regular monitoring of glycaemic control (≥2 HbA1c 
tests per year), lipid profile (≥1 cholesterol test per year) 
and kidney function (≥1 urine albumin-creatinine ratio 
(UACR) test per year).15–17
statistical analyses
We analysed the difference in treatment intensity within 
the first 5 years from date of diagnosis. The study period 
Figure 3 Medication intensity. 
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was subdivided into five annual intervals representing 
year 1 (day 1–day 365) to year 5 (day 1460–day 1825) 
from diagnosis. Sixteen patients whose electronic 
primary care records did not contain information for 
at least one entire year were excluded from the anal-
ysis, resulting in an analysis sample of 173 patients from 
34 GP surgeries with a mean cluster size of 5 patients 
(IT: 82 patients from 18 surgeries, RC: 91 patients from 
16 surgeries). Due to non-availability of data, surgery 
changes and deaths, the total number of complete 
observed patient-years over the follow-up period was 
827 for contact with healthcare professionals and moni-
toring and 737 for prescriptions.
We applied linear regression models separately for 
years 1–5 in order to analyse the difference in the 
number of contacts with GPs and nurses for each 
individual year. A multilevel linear regression model 
accounting for repeated observations (years 1–5) 
within patients was applied to test the overall differ-
ence in the number of annual contacts between the 
study arms over the 5-year study period. This model 
included an interaction term between the year since 
diagnosis and the treatment to capture any time–
treatment interactions.
In parallel with the linear regression models for the 
frequency of contacts with healthcare professionals, 
Figure 4 Medication adherence.
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logistic regression models were applied to assess the 
likelihood of receiving continuous medication (≥4 
prescriptions annually). In a secondary analysis, we also 
examined the likelihood of receiving regular monitoring 
of glycaemic control, lipid profile and kidney function 
and the likelihood of seeing a dietitian.15–17
Linear and logistic regression models were adjusted 
for age and sex and accounted for patients being 
clustered into surgeries (two-level model for strat-
ified analyses and three-level models for overall 
analyses). As the non-random selection of the anal-
ysed subsample does not exactly represent the study 
population, we tested in a sensitivity analysis if the 
introduction of a weighting factor (inverse prob-
ability of being included in the study based on the 
status of having a primary endpoint) has an impact 
on the results. We also altered the thresholds for the 
definition of ‘continuous’ medication (from 4 to 2, 6 
and 12 prescriptions) to assess the sensitivity towards 
these threshold definitions. To assess the sensitivity 
to missing data, we further refitted the analyses to 
a regression-based multiple-imputed (n=10 imputa-
tions) data set (n=189 patients). Statistical analyses 
were performed with SAS V.9.3 using the GLIMMIX, 
MI and MIANALYZE procedures.
To gain a more detailed insight into the pattern of 
GPs’ adherence to treatment algorithms, we further 
extracted clinical information including HbA1c, BP, 
cholesterol, triglycerides, prevalent CVD (defined as 
myocardial infarction or stroke) and 10-year modelled 
coronary heart disease (CHD) risk (using the United 
Kingdom Prospective Diabetes Study (UKPDS) risk 
engine V.2) from the baseline, year 1 and year 5 
examinations of the ADDITION study. Missing clin-
ical values were imputed by the methods of last obser-
vation carried forward and first observation carried 
backwards to avoid shrinkage of the sample size. We 
calculated the proportion of patients who should 
have received medication, that is, the proportion of 
patients whose clinical values exceeded the thresholds 
referred to in the trial protocol10 and the national 
guidelines15–17 (p (clinical value ≥threshold)) and 
the proportion of patients who actually received at 
least one prescription in a time frame of 3 months 
after the date of the laboratory measurement (p 
(number of prescriptions ≥1)) (table 1). We finally 
defined the adherence of GPs to the trial protocol/
national guidelines descriptively as the proportion 
of patients who receive at least one prescription, out 
of those patients whose clinical values exceed the 
thresholds (p (number of prescriptions ≥1) | (clinical 
value ≥threshold)).
results
baseline sample characteristics
Characteristics of the sample at baseline are shown in 
table 2. The mean age of the sample was 62 years, 34% 
were female and 96% Caucasian. The biomedical charac-
teristics of the comparison arms were balanced. No differ-
ences were observed between the full sample (n=189) 
and the analysis sample (n=173).
Contact with healthcare professionals
The adjusted mean number of annual GP and nurse 
contacts is graphically illustrated in figure 2. We found 
no difference in the mean annual number of contacts 
with GPs (IT: 5.80 vs RC: 5.15, β=0.65 [95% CI 
−0.95 to +2.26] or nurses (IT: 5.34 vs RC: 5.49, β=−0.15 
[95% CI −1.77 to +1.48]) and no statistically signifi-
cant trend over time.
Medication
The proportion of GPs who regularly prescribed (≥4 
times annually) glucose-lowering and cardioprotective 
drugs and ORs for the likelihood of regular prescriptions 
are shown in figure 3.
GPs in the IT arm were 3.27 [95% CI 1.81 to 5.93] 
times more likely to regularly prescribe glucose-low-
ering medications compared with GPs in the 
RC arm. However, this difference diminished over 
the follow-up period as more patients in the RC arm 
were also prescribed medication. Patients in the 
IT arm also had a greater chance of being prescribed 
lipid-lowering medication (OR=2.42 [1.30 to 4.51]) 
and ACE-inhibiting drugs (OR=2.03 [1.13 to 3.65]), 
which were, in contrast to routine care guidelines, the 
first choice BP-lowering drug according to the trial 
protocol. But no significant difference was observed 
between the trial arms for the category of BP-lowering 
drugs as a whole (including beta-blocker, diuretics 
and so on) (OR=1.41 [0.71 to 2.80]) (see online 
supplementary appendix 1). No significant difference 
was observed between the trial arms for prescription 
of aspirin. Overall in both treatment arms, the likeli-
hood of patients receiving glucose-lowering, ACE-in-
hibiting and lipid-lowering medications increased 
from diagnosis to 5-year follow-up.
Monitoring of risk factors
The proportion of patients receiving regular HbA1c tests 
(≥2 annually, 45% of patients), lipid tests (≥1 annually, 
55% of patients) and UACR tests (≥1 annually, 75% of 
patients) was low. No significant difference was observed 
between the treatment arms (HbA1c tests: OR=1.56 
[0.63 to 3.83], lipid tests OR=1.53 [0.51 to 4.60] and 
UACR test: OR=0.82 [0.34 to 1.98]) (see online supple-
mentary appendix 1).
sensitivity analysis
Analyses of multiple-imputed data sets led to qualitatively 
and quantitatively similar results. Also the introduction 
of a weighting factor to account for non-random patient 
selection yielded comparable results. Using different 
thresholds for the definition of ‘continuous medica-
tion’ showed that the results for glucose-lowering and 
lipid-lowering medications were not sensitive to threshold 
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definitions. However, increasing the threshold number 
for lipid-lowering drugs attenuated the respective OR 
considerably (online supplementary appendix 2).
Adherence to prescription algorithms
The proportions of patients who should have received 
medication according to national guidelines and the 
ADDITION trial protocol and the proportions of 
patients who actually received a prescription within 3 
months following the assessment of biomedical data are 
presented in column 1 and column 2 of figure 4: The 
black part in column 2 represents the proportion of 
patients who received a prescription and whose clinical 
values exceeded the thresholds for medication prescrip-
tion, and the framed white part represents the propor-
tion of patients who received medication, although 
clinical values did not exceed the thresholds. Adher-
ence to the prescription algorithms, that is, the propor-
tion of patients who received at least one prescription 
out of those patients whose clinical values exceeded the 
thresholds (p (number of prescriptions ≥1) | (clinical 
value ≥threshold)) is shown numerically in the lower part 
of figure 4.
Due to tighter algorithms in the trial protocol (IT arm) 
than in the national guidelines (RC arm), more patients 
in the IT arm were eligible for glucose-lowering, BP-low-
ering and aspirin therapy than in the RC arm. However, 
despite lower cholesterol thresholds in the IT arm 
compared with the RC arm, treatment with lipid-lowering 
medication was indicated in almost equal proportions of 
patients in the two treatment arms.
Glucose-lowering drugs
In the first year, the adherence to the treatment algorithm 
was generally low, but considerably higher in the IT arm 
than in the RC arm. At year 5, 73% of patients in both 
treatment arms with an HbA1c ≥ threshold level received 
a prescription.
BP-lowering/ACE-inhibiting drugs
In the IT arm, adherence to the guideline for prescrip-
tion of ACE-inhibiting medication increased from 41% 
at baseline to 77% at year 5. In the RC arm, guideline 
adherence for prescription of any BP-lowering medica-
tion increased from 55% at baseline to 94% at year 5, and 
‘prescription adherence’ to ACE-inhibiting medication 
(ACE inhibitors were not mentioned in the guidelines to 
be the first-line treatment in RC) increased from 28% at 
baseline to 64% at year 5 (not shown). Of note, a large 
proportion of patients in the RC arm with BP levels below 
the threshold were prescribed BP-lowering medication.
Lipid-lowering drugs
Adherence to the treatment algorithms increased in both 
treatment arms and was consistently better in the IT arm. 
At year 5, most patients with clinical values greater than 
the threshold levels were treated (IT arm 93%, RC arm 
81%).
Aspirin
The adherence to the trial protocol/guidelines was low; 
less than 50% of eligible patients in both treatment arms 
received aspirin.
DIsCussIOn
summary
ADDITION is a large pragmatic primary care-based trial 
aiming to promote intensive multifactorial treatment of 
patients with screen-detected diabetes by GPs. Utilising 
electronic primary care records of patients, this study 
shows that GPs in the IT arm did not see their patients 
more often, but were more likely to regularly prescribe 
metabolic and cardioprotective drugs. Generally, GPs’ 
adherence to prescription algorithms increased substan-
tially in both trial arms over the 5-year follow-up period. 
The substantial time–treatment interaction for prescrip-
tion of glucose-lowering medication indicate that back-
ground changes in routine care might have diluted the 
difference in treatment intensity over time.
Contextual frame
Pragmatic (‘effectiveness’) trials seek to produce exter-
nally valid results in order to inform the process of deci-
sion-making by policy makers.22–25 However, unlike in 
explanatory (‘efficacy’) trials, adherence to protocol 
is rarely tightly monitored and the degree to which the 
intervention is implemented often remains uncertain. 
In the case of non-statistically significant results, this 
begs the question whether the intervention is per se not 
efficacious in the tested (heterogeneous) population, 
or whether the intended difference in treatment inten-
sity was not big enough to detect any effects in the given 
sample size.
Lack of a difference in the intensity of treatment can 
be due to different reasons. First, adherence of respon-
sible healthcare professionals to the protocol might be 
low due to limited motivation, insufficient resources or 
lack of interest in the ongoing trial. To tackle this issue, in 
ADDITION-Cambridge, a detailed trial protocol was spec-
ified and the implementation of the protocol elements 
was incentivised by additional monetary resources and 
supported by an initial practice-based academic and two 
interactive feedback sessions.10
Second, treatment delivered in everyday practice 
might differ from both guidelines and what happens in 
research-active practices. Not considering actual practice 
in routine care can result in intervention plans that fail 
to induce treatment differences between the trial arms. 
The choice of suitable interventions is therefore particu-
larly challenging in multinational trials like ADDITION, 
where guidelines or daily practice in countries might 
differ, but a certain degree of intervention homogeneity 
is warranted.9
Third, policy changes, such as changes in the remu-
neration system and modifications in treatment guide-
lines, can intensify routine care, thus potentially diluting 
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differences between the intervention and routine care 
arm. Long-term trials such as ADDITION are particularly 
susceptible to such influences. Between 2003 (~start of 
the study) and 2008/2009 (~end of the 5-year analysis 
period) in the UK, no new national diabetes treatment 
guidelines were released. However, in 2004 the QOF 
with its pay for performance system was launched18 and 
extended in the following years. The QOF incentivised 
fulfilment of basic quality of care indicators by monetary 
resources and may have improved the quality of care for 
patients with various conditions, including diabetes.20 26
Principal findings
Our study shows that although surgeries in the IT arm 
received monetary resources for additional consultations, 
GPs and nurses did not see their patients more often, nor 
were they more likely to perform regular HbA1c, lipid or 
UACR tests. This result might be explained by the fact 
that the patients in the RC arm already saw their GP/
nurse on average five to six times a year, which is more 
than the average ~4 GP and ~2.5 nurse contacts per year 
for the general UK population.27 Therefore the GPs (and 
indeed the patients) may have felt that this was sufficient 
to adequately monitor the condition. It also shows that 
monetary incentives might help to convince a reasonable 
number of surgeries to participate in long-term extensive 
trials such as ADDITION (46% of contacted surgeries 
agreed to join the study), but that financial incentives 
might not be successful in motivating GPs to further 
increase treatment intensity if it is already at a high level.10 
Qualitative interviews with the GPs about their perspec-
tives on the intervention, as conducted in the screening 
phase of the ADDITION study,28 would have been a valu-
able add-on to address this question. In contrast, our 
results indicate that the education sessions and feedback 
audits had a positive impact on the protocol adherence 
of GPs, as general adherence to the treatment algorithms 
in the IT arm was higher than adherence to the national 
guidelines in the RC arm. This finding supports previous 
research that feedback loops can help to maximise guide-
line adherence in primary care.29 30
According to the clinical thresholds outlined in the 
trial protocol and the national guidelines, more patients 
in the IT arm than in the RC arm were eligible to receive 
glucose-lowering, BP-lowering and platelet-inhibiting 
drugs (figure 4). This suggests that the ADDITION inter-
vention was designed at an appropriate level for the 
context, as even with a hypothetical prescription adher-
ence of 100%, patients in the IT arm should have received 
more intensive treatment than patients in the RC arm.
Notably, a very high proportion of patients in the 
RC arm already received BP-lowering medication at 
baseline, although in many cases their BP levels did not 
exceed thresholds. The finding of high BP-lowering 
prescription prevalence probably results from the fact 
that treatment with BP-lowering medication was part 
of the risk score used to identify high-risk individuals 
eligible for diabetes screening in the first phase of the 
ADDITION trial.10 There could be two reasons why many 
of the patients who received BP-lowering prescriptions 
had no apparent clinical indication for treatment. On 
the one hand, these patients might have previously had 
uncontrolled BP levels, but treatment with BP-lowering 
medication brought their BP under control. On the other 
hand, it is possible that the daily practice for BP control 
at this time was already much stricter than recommended 
by the guidelines. Independent of its origin, the initially 
high prevalence of BP-lowering medication in both trial 
arms might be the reason why we did not observe a differ-
ence in the proportion of patients prescribed BP-low-
ering drugs. Consequently, the observed difference in 
ACE-inhibiting drugs may be due to GPs switching from 
diuretics or beta-blockers to ACE-inhibiting drugs, as 
recommended by the trial protocol.
The low adherence to recommendations concerning 
aspirin therapy observed in both trial arms is inter-
esting, as this prescription behaviour could be inter-
preted as a general scepticism among GPs (and perhaps 
patients) towards the weak evidence of benefits of 
aspirin therapy for primary prevention of cardiovas-
cular disease.6 The results of subsequent large trials 
justify such scepticism.31 32 Alternatively, some patients 
may have obtained aspirin from the pharmacy without a 
prescription without this being noted in the electronic 
medical record.
Except for aspirin, adherence to prescription algo-
rithms increased substantially over the follow-up period. 
We assume that this finding is triggered by the progression 
and duration of the disease and by general improvements 
in the overall quality of care over time, independent 
of disease progression.33 The significant interaction 
between ‘treatment’ and ‘time since diagnosis’ for 
glucose-lowering medication indicates changing treat-
ment patterns in the RC arm, which might be triggered by 
policy changes, like QOF. However, due to methodolog-
ical limitations (covariate collinearity, power problems in 
stratified models), this question could not be adequately 
addressed with the available data.
Implications for the planning of future pragmatic trials
This study shows that the successful implementation 
of a pragmatic trial in primary care is possible, but 
there are issues that need to be considered, namely 
(1) a high standard of care in control GP surgeries 
that questions the need for further intensification, 
(2) treatment of patients in the RC arm that did not 
reflect the national guidelines, and (3) background 
policy changes affecting quality of routine care. These 
issues need to be identified, considered and addressed 
when designing a pragmatic study or rolling out an 
intervention comprehensively.23 24 34 The results further 
underline the potential importance of standard good 
practice in (pragmatic) trials. Methods such as initial 
academic detailing and repeated feedback sessions 
may be of great importance for the overall success 
of the study.24 35 In this context, more qualitative or 
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quantitative implementation research may help to 
identify and test strategies that affect the adherence of 
healthcare professionals (and patients).36
Ideally, pragmatic trials of complex interventions 
should, if possible, be designed in a way that allows eval-
uation of the adherence of healthcare professionals to 
the trial protocol and of patients to the chosen treat-
ment regimen. This study shows that the use of electronic 
primary care records is a promising approach to assess the 
adherence of GPs. The obtained data are also useful for 
health economic research. In this particular example, the 
new primary care data can be used to update a previous 
analysis to reduce uncertainty in the cost-effectiveness of 
the intervention,37 38 a method consistent with an iterative 
approach to research and adoption decisions.39–41
Implications for the interpretation of trial results
Intensified prescription algorithms were well imple-
mented into practice. We found that prescription with 
glucose-lowering, ACE-inhibiting and lipid-lowering 
drugs was higher in the IT arm. The expected treatment 
effect resulting from this difference in medication could 
be interpreted as an area under the curve issue: The 
combination of the magnitude and the duration of the 
treatment difference can be expected to be the crucial 
driver of long-term effects. The extended follow-up of 
the UKPDS trial, which aimed to reduce diabetes-related 
complications through tighter glucose and BP control, 
has shown that after the termination of the interven-
tion, between-group differences in laboratory measure-
ments disappeared.42–45 However, the reductions in 
risk of microvascular and macrovascular complications 
persisted (or increased) for patients who had received 
tight glucose control, but not for patients who had 
received tight BP control.42 43 In ADDITION we observed 
a small but significant improvement in HbA1c, BP and 
cholesterol levels in the IT arm and a non-significant 
reduction in risk of the composite CVD endpoint (Rela-
tive Risk =0.83, p=0.12) over a 5-year time period.14 This 
study shows that the proportion of patients receiving 
glucose-lowering drugs in each arm had equalised at the 
end of the 5-year observation period, suggesting that 
the differences in glycaemic control might disappear in 
the subsequent years. However, as a substantially greater 
proportion of patients in the IT arm received ACE-in-
hibiting and lipid-lowering drugs, it can be assumed 
that differences in BP and lipids might be sustained. 
If between-group differences in treatment for BP and 
lipids diminish, so will the levels of risk factors. However, 
the CVD risk may remain lower due to legacy effects of 
earlier reductions in glucose and cholesterol. Given that 
the number of events will also increase over time, it may 
be that the ADDITION intervention will show a statis-
tically significant effect in the long term; the 10-year 
follow-up of ADDITION will quantify the long-term 
effect of relatively small differences in treatment and 
risk factors observed in the first 5 years after diagnosis of 
diabetes by screening.14
strengths and limitations
To our knowledge, this is one of the first studies to 
comprehensively analyse the adherence of GPs to a 
pragmatic trial protocol in primary care. In contrast to 
self-reported information from patients, electronically 
stored primary care records provide a high degree of 
detail about all GP-based primary care services deliv-
ered to patients and are less susceptible to recall bias.46 
Through the linkage of clinical information from the 
trial measurements with information on prescriptions 
from the electronic primary care records, it was further 
possible to comprehensively describe and analyse the 
prescription adherence of GPs to the trial protocol 
and to national guidelines.
However, we only had data from a subsample of 
the ADDITION-Cambridge trial cohort with an over-
sampling of patients with a primary event during the 
follow-up period. As our weighted sensitivity analyses 
showed that this issue did not affect the results, the 
findings of this study are likely to be generalisable to 
the sample of GP surgeries who participated in the 
ADDITION trial. Nevertheless, the generalisability 
of results to average GP surgeries in the UK might be 
quite limited. In the experience of the authors, the 
practices that take part in research tend to be more 
organised and deliver better quality routine care than 
those declining to participate. This might lead to 
ceiling effects for interventions, that is, it appears to 
be hard to induce a difference in treatment intensity 
between RC and a more intensive treatment regimen.
Another limitation is that in our assessment of 
prescription adherence, we did not take into account 
possible contraindications for medications as well as 
patients’ views, and analysed the data from a rather 
non-situational, disease-orientated perspective.47 48 
Shared decision making between the GP and the patient 
might reasonably lead to decisions that deviate from 
those in the protocol (and national guidelines). We 
therefore do not know if patients or GPs were the main 
determinants of protocol non-adherence. It is possible 
that patients did not agree to start medication or to 
come to the surgery more often. To completely under-
stand the adoption of the intervention, the patient’s 
role also needs to be taken into account, which was 
impossible with the chosen approach. Also, with the 
given data we could not evaluate the fidelity of GPs 
handing over the educational materials to study partic-
ipants, which were also part of the intervention.
Finally, although the accuracy of primary care records 
for GP-based services is known to be quite high, partic-
ularly for prescribed medication and laboratory tests, 
the handling, merging and extraction of free text data 
from numerous observations (~80 000) originating from 
different IT format systems are challenging and valida-
tion was not undertaken.46 Consequently, it is possible 
that a small proportion of services might be misclassified, 
resulting in non-differential bias.
 o
n
 12 N
ovem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-015295 on 14 June 2018. Downloaded from 
11Laxy M, et al. BMJ Open 2018;8:e015295. doi:10.1136/bmjopen-2016-015295
Open access
COnClusIOn
This study demonstrates that the successful implemen-
tation of long-term pragmatic trials in primary care 
is possible, but there are many obstacles especially 
during periods of significant change in routine care. 
The retrospective analyses of the electronic primary 
care records of participants in the ADDITION-Cam-
bridge trial show that intensive treatment was fairly 
well implemented into practice, suggesting that posi-
tive effects on cardiovascular morbidity and mortality 
might be expected in the long term. Where possible, 
data needed to evaluate the fidelity of stakeholders to 
trial protocols should be collected routinely in future 
pragmatic trials as this information is invaluable for 
the interpretation of study results and for the plan-
ning of future studies.
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